| Original language | English (US) |
|---|---|
| Pages (from-to) | E422-E425 |
| Journal | American journal of hematology |
| Volume | 97 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 2022 |
ASJC Scopus subject areas
- Hematology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: American journal of hematology, Vol. 97, No. 11, 11.2022, p. E422-E425.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study
AU - Jonas, Brian A.
AU - DiNardo, Courtney
AU - Fracchiolla, Nicola
AU - Pristupa, Alexander
AU - Ishizawa, Kenichi
AU - Jin, Jie
AU - Konopleva, Marina
AU - Ofran, Yishai
AU - Montesinos, Pau
AU - Kovacsovics, Tibor
AU - Jang, Jun Ho
AU - Kantarjian, Hagop
AU - Duan, Yinghui
AU - Potluri, Jalaja
AU - Werner, Michael
AU - Pratz, Keith W.
N1 - Funding Information: Brian A. Jonas: Consultancy/advisory role for AbbVie, BMS, Genentech, Gilead, GlycoMimetics, Jazz, Pfizer, Servier, Takeda, Tolero, and Treadwell; protocol steering committee for GlycoMimetics; data monitoring committee for Gilead; travel reimbursement from AbbVie; research funding to institution from 47, AbbVie, Accelerated Medical Diagnostics, Amgen, AROG, BMS, Celgene, Daiichi Sankyo, F. Hoffmann‐La Roche, Forma, Genentech/Roche, Gilead, GlycoMimetics, Hanmi, Immune‐Onc, Incyte, Jazz, Loxo, LP Therapeutics, Pfizer, Pharmacyclics, Sigma Tau, and Treadwell. Courtney DiNardo: Consultant and on Advisory Boards for AbbVie, Agios, Aprea, Celgene/BMS, ImmuneOnc, Kura, Novartis, Takeda, Notable Labs; research support provided to her institution by AbbVie, Agios, Calithera, Cleave, BMS/Celgene, Daiichi‐Sankyo, ImmuneOnc, Loxo. Nicola Fracchiolla: Honoraria from Amgen, Pfizer, Gilead, and AbbVie; speakers' bureau for Amgen, Pfizer, and Gilead; board of directors or advisory committee membership with Amgen, Pfizer, Gilead, and AbbVie; travel accommodations and expenses from Amgen, Pfizer, Gilead, and AbbVie. Alexander Pristupa: Employment with State Institution of Health of the Ryazan Regional Clinical Hospital; speakers' bureau with Takeda and Pfizer; research funding from Takeda, Pfizer, Janssen, AbbVie, Daiichi Sankyo, Paraxel, Acerta, Pharmacyclics, Geron, and Beigene; honoraria from Takeda, Pfizer, Janssen, AbbVie, Daiichi Sankyo, Paraxel, Acerta, Pharmacyclics, Geron, and Beigene. Kenichi Ishizawa: Honoraria from Takeda, Ono, Chugai, Eizai, Novartis, and Celgene; research funding from SymBio, Bayer, AbbVie, and Novartis. Jie Jin and Jun‐Ho Jang: Nothing to disclose. Marina Konopleva: Consultancy/advisory role with AbbVie, Genentech, F. Hoffmann La‐Roche, Stemline Therapeutics, Forty‐Seven, Amgen, and Kisoji; research funding from AbbVie, Genentech, F. Hoffmann La‐Roche, Stemline Therapeutics, Forty‐Seven, Eli Lilly, Cellectis, Calithera, Ablynx, Agios, Ascentage, AstraZeneca, Rafael Pharmaceutical, and Sanofi; royalties, stock, and other options from Reata Pharmaceutical Inc.; patents and royalties with patent US 7795305 B2 on CDDO‐compounds and combination therapies, licensed to Reata Pharmaceutical. Yishai Ofran: Consultancy/advisory role for Pfizer, AbbVie, Novartis, Astellas, and Roche; board of directors or advisory committee membership with AbbVie, Novartis, and Pfizer. Pau Montesinos: Consultancy/advisory role for Celgene, Pfizer, and AbbVie; research funding from Pfizer, AbbVie, and Daiichi Sankyo; speakers' bureau with Astellas, Novartis, and Janssen. Tibor Kovacsovics: Honoraria from Agios, Astella, and Jazz; research funding from AbbVie, Glycomimetics Novartis, and Pfizer. Jun‐Ho Jang: Honoraria from Novartis and Amgen. Hagop Kantarjian: Research funding from AbbVie, Amgen, Ascentage, Bristol Myers Squibb, Daiichi‐Sankyo, Immunogen, Jazz, Novartis; honoraria from AbbVie, Amgen, Ascentage, Astellas, Astrazeneca, Biologix, Curis, Ipsen Biopharmaceuticals, KAHR Medical, Novartis, Pfizer, Precision Biosciences, Shenzhen Target Rx, and Taiho Pharma Canada. Yinghui Duan, Jalaja Potluri and Michael Werner: AbbVie employees and may own stock or stock options. Keith W. Pratz: Consultancy/advisory role for AbbVie, Astellas, Boston BioMedical, Bristol Myers Squibb, Novartis, Jazz Pharmaceuticals, Servier, and Celgene; research funding from AbbVie, Agios, Daiichi Sankyo, and Millennium.
PY - 2022/11
Y1 - 2022/11
UR - http://www.scopus.com/inward/record.url?scp=85138190135&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85138190135&partnerID=8YFLogxK
U2 - 10.1002/ajh.26707
DO - 10.1002/ajh.26707
M3 - Article
C2 - 36053878
AN - SCOPUS:85138190135
SN - 0361-8609
VL - 97
SP - E422-E425
JO - American journal of hematology
JF - American journal of hematology
IS - 11
ER -